TrialEndocrine2012

Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.

Christoph Beglinger et al.PubMed ↗Publisher ↗

No numbers read from the abstract.